Vitae Biomedical Co., Ltd. has been honored with the National Innovation Award for the fifth consecutive year, reflecting sustained progress in its research and development of non-invasive diagnostic technologies.

This continued recognition highlights the company’s long-term commitment to advancing core technologies and optimizing its detection platform. Rather than representing a single achievement, the five-year record underscores a consistent and disciplined approach to innovation, execution, and product development.

Vitae Biomedical has focused on developing urine-based biomarker detection and non-invasive diagnostic platforms, while actively expanding its international collaboration network. In recent years, the company has engaged with partners in Japan to explore clinical integration and market adoption strategies, and with institutions in Lithuania to support cross-border clinical validation and research.

These ongoing efforts demonstrate the company’s ability to translate innovation into real-world applications, bridging research, clinical validation, and market development. The recognition further reinforces its position as a reliable partner in advancing early detection and precision medicine.

Looking ahead, Vitae Biomedical will continue to strengthen its technology platform and collaborate with healthcare and industry partners to accelerate the adoption of innovative diagnostics, contributing to improved public health outcomes.